Health Archive » April, 2010

Health - April, 2010

198 articles

• FDA Dropped Ball On Heparin Probe: GOP Lawmakers
• Watson Faces Suits Over Trilipix, Rapamune ANDAs
• Anthem Withdraws Rate Hike After Errors Found
• Wyeth, Schwarz Escape Reglan Failure-To-Warn Suit
• Law Firms Prepare For Wave Of Health Care Work
• Axiom Off Hook For Infringement Of Electrotherapy IP
• Hospital Can Sue Rival On Antitrust Grounds: 11th Circ.
• Neurontin Purchasers Ask To Amend Class Definition
• J&J Unit Settles Off-Label Marketing Claims For $81M
• 2nd Circ. Urges En Banc 'Pay-For-Delay' Rehearing
• Lasik Patients Oppose TLC Vision Ch. 11 Plan
• Grassley Pushes For Post-Market Drug Safety Measures
• Schwarz Pays $22M To Settle Medicare Fraud Cases
• CellCyte CEO Fraud Claims Can Move Forward
• Grassley Pushes States To Beef Up False Claims Acts
• Dentsply Strikes Deal To Avoid Antitrust Trial
• Medtronic To Buy ATS Medical In $370M Deal
• Allstate Challenges Wyeth Win In Ativan Coverage Suit
• King & Spalding Lures Sidley Health Industry Pro
• Sandoz Resolves Takeda Patent Dispute Over Actos
• Fed. Circ. Upholds Invalidity Of J&J Concerta Patent
• More Plaintiffs Tossed From ReNu Lens Solution MDL
• WellPoint Ends Rescission, Delays Rate Hikes
• 5 Things Patent Examiners Wish You Would Do
• Forest, Orchid Resolve Namenda Patent Fight
• Boston Scientific Stent Fraud Class Action Tossed
• Abbott, Lilly, Others Hid Miscarriage Drug's Risks: Suit
• A Path To Accountable Care Runs Through The FTC
• CIBA Loses Injunction Bid In Acuvue Case
• Vioxx Ruling A Boost For Securities Suits: Attys
• Alcon Settles Synergetics Tying Suit For $32M
• 280K Defibrillators At Risk For Malfunction, FDA Warns
• Biotest Contract Suit Over Nabi-HB Remains In Fla.
• Guidant's $296M Plea Deal In Defibrillator Case Rejected
• Fed. Circ. Nixes $4.4M In Sanctions Against McDermott
• FTC Adds More Defendants To Government Grant Case
• Avigen, MediciNova Settle Shareholder Suit Over Deal
• The EU Probe Into Pharmaceutical Patent Settlements
• Teva Attacks Watson Over Generic Menopause Drug
• Novartis Manager Withheld Info About Employee's Rape
• AstraZeneca Set To Seal $520M Deal In Seroquel Case
• FDA Unveils New Analysis Rules For Medical Devices
• Shire Targets Teva Over Generic Intuniv
• Drugstores Ask Court To Reconsider Plavix Ruling
• Fed. Circ. To Review Inequitable Conduct Standards
• Davis Polk Reps Charles River In $1.6B WuXi Deal
• Suit Accusing Amgen Of Kickbacks Gets The Boot
• Clients Say Fen-Phen Lawyer Overcharged $29M
• Abbott, Hospira Off Hook In ERISA Class Action
• Latham Advises Thoratec In $136M Danaher Deal
• Aetna, Humana Latest To Settle In OxyContin MDL
• Celgene, Novartis Settle With Barr Over Generic Ritalin
• Jury Finds Pfizer's Protonix Patent Valid
• WebMD Affiliates Fail In Appeal Over Fraud Coverage
• Class Cert. Stripped In Fla. Doctor Bonuses Suit
• Pay-For-Delay Deals Remain In FTC's Crosshairs
• UBS, E&Y To Pay $250M In HealthSouth Fraud Case
• FDA Takes Action To Reduce Infusion Pump Risks
• HHS To WellPoint: Don't Drop Breast Cancer Patients
• 'Most Favored Nation' Clauses And Health Insurers
• Group Asks SEC To Review CVS Stock Sales
• WellPoint Unit Denied Profits On Health Plan Rates
• Medtronic Recall Earns FDA's Most Serious Rating
• Focalin IP Deal Between Celgene, Actavis Wins OK
• Wal-Mart Medical Treatment Action Stayed For Appeal
• Northern Ill. Patent Rules Have Yet To Boost Filings
• Watson Appeals Loss In Seasonique Spat With Teva
• $4.5M MediCor D&O Settlement Approved
• Trademark Owners Must Watch Out Post-MedImmune
• Pfizer Responds To FDA Over Geodon Clinical Trial
• Philips Fails To Keep Antitrust Claims In Oximeter Suit
• St. Jude Settles Doctor's Pacemaker Patent Action
• Bayer Drops Case Against Lupin Over Generic Cipro
• Senator Wants To Snuff Out Candylike Tobacco
• Congressional Testimony: What To Do (And Not Do)
• Boehringer Pays $7.75M To Settle AWP Allegations
• Salt Report Spurs FDA To Form Attack Plan
• New Damages Trial Granted In Wal-Mart Medicine Suit
• Obama Taps Harvard Prof. To Run Medicare, Medicaid
• Ex-Tenet GC Defeats Medicare False Claims Suit
• 3 Claims Of Schering's Zetia Patent Found Invalid
• Synthon Seeks To Shift Lilly Adcirca Battle To NC
• Steris Offers Device Rebates To Settle FDA Claims
• BarrierMed CEO Settles SEC $11M Fraud Suit
• Howmedica Faulty Hip Implant Suit Preempted: Judge
• No Cert For Fresenius In Baxter Dialysis Patent Case
• Eli Lilly To Buy Back Cymbalta Rights For $400M
• Pfizer, Wyeth Antitrust Complaint Nixed For 3rd Time
• Mars Sues Supplement Makers Over Cocoa Patents
• Miss. High Court Revives State AWP Suit Against Bayer
• Biovail Files 2nd Suit Over Watson's Aplenzin ANDA
• Reverse Payments, Mergers Take Center Stage In Q1
• High Court Remands Class Action, Citing Shady Grove
• MDL Panel Won't Centralize Pain Pump Suits
• 3rd Circ. Upholds Dentsply Wins In Antitrust Cases
• Secondary Payor Liability In Settling Medicare Claims
• Drugstores Denied Injunction In Calif. Medicaid Suit
• Novartis, Astellas, GSK Ads Misbranded Drugs: FDA
• Lundbeck Notches Win In Danish Cipralex Case
• Biovail Hits Paddock With 2nd Suit Over Aplenzin ANDA
• Davis Polk Reps Oracle In $685M Phase Forward Deal
• Mayo Foundation, Philips Clear Up Imaging Patent Spat
• No Stay For Apotex Amid Sanofi's Plavix Damages Push
• MedQuist, CBay Get Bankrupt Spheris For $116M
• Insurer Wants Quick Appeal In $7M MedAssets Suit
• Fed. Circ. Rules Use Code Off Limits In Prandin IP Case
• Insurers Will Try To Dodge Spending Reforms: Report
• NYC's St. Vincent's Files Ch. 11 Amid Closures
• Ranbaxy's US Branch Recalls Antibiotics Over Color
• Viagra Study Documents Can't Be Released: Judge
• Santarus' Patents For Heartburn Drug Invalid: Judge
• GSK Asks Again For Dismissal Of Wellbutrin IP Claims
• AstraZeneca Loses Bid To Nix Toprol Antitrust Suits
• Ill. Patients Appeal Denied Antitrust Class Cert. Bid
• Exclusive Gene Patents Can Hurt Competition: Study
• Sens. Grill Holder On Securities, Health, Antitrust
• Pozen, Teva Bury Hatchet Over Treximet
• Stryker Surgical Implant Kickback Suit Loses Legs
• Counsel Accused Of Improper Conduct In Fraud Case
• Case Over GE's Omniscan Survives Dismissal Bid
• Home Care Workers Sue NYC Agency For OT Wages
• The Economic Impact Of New MMSEA Regulations
• Ga. Joins States' Health Care Suit Over AG's Refusal
• Blue Cross Mich. Agrees To Cover Autism Therapy
• Bayer Updates Blood Clot Risk Info For Yasmin Label
• Endo, Penwest Reach Opana License Deal With Barr
• FDA Proposes Rules For Listing Side Effects In Ads
• Perrigo, Graceway Strike Deal Over Generic Aldara
• K-Dur Direct Purchasers Appeal Antitrust Suit Ruling
• A Viable Theory Of Sham Infringement Litigation?
• Boston Sci Misled Investors After Guidant Deal: Suit
• $110M E-Ferol Settlement Gets Final Approval
• Recapture Rule Dooms 4 Claims Of MBO Syringe Patent
• GSK, Glenmark Resolve Malaria Drug Patent Dustup
• Boston Sci Appeals Cordis Stent Patent Win
• Nationwide To Settle With Fixed-Pay Insurance Class
• Health Care Reform And 'Grandfathered Plans'
• Perrigo Triumphs In Trial Over Rexall's False Ad Claims
• Congress To Study Smokeless Tobacco Use In MLB
• Applied Medical Fights $4.8M Verdict In Surgery IP Suit
• Cohen Milstein OK'd As Counsel In Plasma Pricing MDL
• Warner Chilcott, Roche Sue Mylan Over Actonel ANDA
• Another Weapon In The Midsize Firm Arsenal
• Novartis Ignored Consultant's Sex Bias Findings: Atty
• Radiation Therapy Devices Face FDA Scrutiny
• Medtech, DenTek Resolve Mouth Guard Patent Battle
• Smith & Nephew Seeks New Trial In Kinetic IP Suit
• FDA Warns Edwards Over Heart Device Reporting
• Fed. Circ. Upholds Icos' Ownership Of Cialis Patents
• Bioenvision Shareholder Suit Rightly Nixed: 2nd Circ.
• US Oftalmi Recalls Eye, Nose Drops Over Sterility
• Genesis, Shippert End Feud Over Liposuction Patent
• Hemispherx's Hostile Takeover Suit Stays Alive
• FDA Cracks Down On Spas' Lipodissolve Claims
• PharMerica's Contract Interference Suit Survives
• IT Worker Hits Wash. Blue Cross With OT Suit
• Whistleblower Protections Under Health Care Bill
• 3rd Circ. Affirms Slimmer Case Against Ex-BMS Exec
• FDA Warns Gilead, Biogen Over Drug Ads
• J&J, Omnicare Hit With Class Action Over Kickbacks
• 5 More States Join Suit Against Health Care Law
• Novartis Sex Bias Class Action Goes To Trial In NY
• Aware Settles Acacia Unit's Medical Imaging IP Suit
• ITC OKs ENI-Cargill Glucosamine IP Deal In 337 Case
• Health Care Reform Means New Disclosure Rules
• Last Defendants Settle With Sanofi Over Eloxatin
• Bristol-Myers, Takeda Hit With False Marking Suits
• AstraZeneca Win In Seroquel Bellwether Affirmed
• Ace Seeks Zurich Funds For $4M Payout To Worker
• UGA To Pay Inventor $20M Over Restasis Patents
• Purdue Settles Ark. Fund's OxyContin Antitrust Suit
• Guidant Pleads Guilty In Defibrillator Safety Case
• Apotex Asks DC Circ. To Stay Teva's Hyzaar Exclusivity
• Sperm Bank Not Liable For 'Defective' Semen: 3rd Circ.
• Merck Sues Novartis Unit Over Cancidas ANDA
• NeoPharm Investors' Class Action Trimmed
• Ballard Spahr Leads Medegen In $225M CareFusion Deal
• Medtronic To Appeal Edwards' $74M Heart Valve IP Win
• Mayer Brown Off Hook For $17M Malpractice Claim
• Dentsply Must Face Rivals' Federal Antitrust Claims
• Fed. Circ. Bolsters Hearing Components' Audio IP Win
• Pa. Supreme Court Blocks Appeal In Prempro Case
• Venable Shot Down As Counsel For Unsecured Creditors
• Fed. Circ. Further Untangles HIF Bio Inventorship Fight
• Teva's Gemzar ANDAs Infringe Lilly Patent: Judge
• Fed. Circ. Nixes Suit To Invalidate Kinetic Patents
• USPTO Revises Appeal Briefs Procedure
• La. Allowed To Pursue Vioxx Refund From Merck
• Lilly, Sandoz Can't End Generic Prozac Suicide Case
• Sanofi Settles With Teva, Others Over Generic Eloxatin
• FDA Rolls Out Pediatric Info Rule For Device Makers
• Teva Gets Win In Birth Control IP Battle Against Watson
• Hospital, Health Plans End Oxycontin Antitrust Suits
• La. Health Insurance Law Unconstitutional: 5th Circ.
• Novo Nordisk Patent Suit Over Prandin Nixed
• Teva Fights To Keep Exclusivity On Hypertension Drugs
• Lilly Settles La. AG Zyprexa Claims For $20M
• Alternative Fee And Billing Arrangements: A Primer